265 related articles for article (PubMed ID: 11970881)
1. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection.
Baron JL; Gardiner L; Nishimura S; Shinkai K; Locksley R; Ganem D
Immunity; 2002 Apr; 16(4):583-94. PubMed ID: 11970881
[TBL] [Abstract][Full Text] [Related]
2. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
3. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
4. Natural killer T cell activation inhibits hepatitis B virus replication in vivo.
Kakimi K; Guidotti LG; Koezuka Y; Chisari FV
J Exp Med; 2000 Oct; 192(7):921-30. PubMed ID: 11015434
[TBL] [Abstract][Full Text] [Related]
5. Immediate antigen-specific effector functions by TCR-transgenic CD8+ NKT cells.
Wingender G; Berg M; Jüngerkes F; Diehl L; Sullivan BA; Kronenberg M; Limmer A; Knolle PA
Eur J Immunol; 2006 Mar; 36(3):570-82. PubMed ID: 16506291
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
7. CD1d-specific NK1.1+ T cells with a transgenic variant TCR.
Sköld M; Faizunnessa NN; Wang CR; Cardell S
J Immunol; 2000 Jul; 165(1):168-74. PubMed ID: 10861049
[TBL] [Abstract][Full Text] [Related]
8. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance.
Ito H; Ando K; Ishikawa T; Nakayama T; Taniguchi M; Saito K; Imawari M; Moriwaki H; Yokochi T; Kakumu S; Seishima M
Int Immunol; 2008 Jul; 20(7):869-79. PubMed ID: 18487227
[TBL] [Abstract][Full Text] [Related]
9. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers.
Benlagha K; Weiss A; Beavis A; Teyton L; Bendelac A
J Exp Med; 2000 Jun; 191(11):1895-903. PubMed ID: 10839805
[TBL] [Abstract][Full Text] [Related]
10. Control of NKT cell differentiation by tissue-specific microenvironments.
Yang Y; Ueno A; Bao M; Wang Z; Im JS; Porcelli S; Yoon JW
J Immunol; 2003 Dec; 171(11):5913-20. PubMed ID: 14634102
[TBL] [Abstract][Full Text] [Related]
11. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
12. CD1d-restricted NKT cells: an interstrain comparison.
Hammond KJ; Pellicci DG; Poulton LD; Naidenko OV; Scalzo AA; Baxter AG; Godfrey DI
J Immunol; 2001 Aug; 167(3):1164-73. PubMed ID: 11466330
[TBL] [Abstract][Full Text] [Related]
13. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.
Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T
Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881
[TBL] [Abstract][Full Text] [Related]
14. DOCK2 is required in T cell precursors for development of Valpha14 NK T cells.
Kunisaki Y; Tanaka Y; Sanui T; Inayoshi A; Noda M; Nakayama T; Harada M; Taniguchi M; Sasazuki T; Fukui Y
J Immunol; 2006 Apr; 176(8):4640-5. PubMed ID: 16585555
[TBL] [Abstract][Full Text] [Related]
15. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
[TBL] [Abstract][Full Text] [Related]
16. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells.
Duarte N; Stenström M; Campino S; Bergman ML; Lundholm M; Holmberg D; Cardell SL
J Immunol; 2004 Sep; 173(5):3112-8. PubMed ID: 15322171
[TBL] [Abstract][Full Text] [Related]
17. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.
Kawano T; Cui J; Koezuka Y; Toura I; Kaneko Y; Motoki K; Ueno H; Nakagawa R; Sato H; Kondo E; Koseki H; Taniguchi M
Science; 1997 Nov; 278(5343):1626-9. PubMed ID: 9374463
[TBL] [Abstract][Full Text] [Related]
18. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus.
Vilarinho S; Ogasawara K; Nishimura S; Lanier LL; Baron JL
Proc Natl Acad Sci U S A; 2007 Nov; 104(46):18187-92. PubMed ID: 17991774
[TBL] [Abstract][Full Text] [Related]
19. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR.
Grubor-Bauk B; Simmons A; Mayrhofer G; Speck PG
J Immunol; 2003 Feb; 170(3):1430-4. PubMed ID: 12538704
[TBL] [Abstract][Full Text] [Related]
20. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.
Trobonjaca Z; Kröger A; Stober D; Leithäuser F; Möller P; Hauser H; Schirmbeck R; Reimann J
J Immunol; 2002 Apr; 168(8):3763-70. PubMed ID: 11937527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
